Viking Therapeutics Stock News

Viking Therapeutics, Inc. (NASDAQ:VKTX)s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $5.61 and traded as low as $4.86. Viking Therapeutics shares last traded at $5.18, with a volume of 841,181 shares. A number of equities analysts have commented on [] The post Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61 appeared first on ETF Daily News .

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have been given a consensus rating of Buy by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in []

Viking Therapeutics Inc. (NASDAQ:VKTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 5.59% to the previous days close as strong demand from buyers drove the stock to $4.91. Actively observing the price movement in the last trading, the stock closed the session at $4.65, falling within a range of $4.60 Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021? Read More »

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

Calliditas (CALT) obtains accelerated approval for Tarpeyo to reduce proteinuria in IgA nephropathy in the United States.

Foghorn (FHTX) soars following a collaboration with pharma giant Lilly for novel oncology targets.

Bristol-Myers (BMY) increases its quarterly dividend and announces a share repurchase program. Consequently, the stock gains.

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea

Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.

Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea

Metropolitan Life Insurance Co NY grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 47,695.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,559 shares of the biotechnology companys stock after buying an additional 9,539 shares during the quarter. Metropolitan Life []